NCT04479488 (SARS-Brazil) is a clinical trial of Hospital admission in Covid19, sponsored by Hospital Israelita Albert Einstein.

Who is sponsoring NCT04479488?

NCT04479488 is sponsored by Hospital Israelita Albert Einstein.

What drugs are being tested in NCT04479488?

Interventions in NCT04479488: Hospital admission, Non-hospitalization procedures.

What condition does NCT04479488 study?

NCT04479488 studies Covid19, SARS-CoV Infection.

Is NCT04479488 still recruiting?

NCT04479488 is currently completed. Last updated 9 March 2023.

Last reviewed 2023-03-09 · How we verify

NCT04479488: SARS-Brazil

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil)

Completed Last updated 9 March 2023

What this trial tests

trial testing Hospital admission in Covid19 in 1,587 participants. Completed in 30 December 2022.

Timeline

27 July 2020

Primary endpoint
30 March 2021

30 December 2022

Quick facts

Lead sponsor	Hospital Israelita Albert Einstein
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,587
Start date	27 July 2020
Primary completion	30 March 2021
Estimated completion	30 December 2022
Sites	14 locations across Brazil

Drugs / interventions tested

Hospital admission
Non-hospitalization procedures

Conditions studied

Covid19 — all drugs for Covid19 →
SARS-CoV Infection — all drugs for SARS-CoV Infection →

Sponsor

Hospital Israelita Albert Einstein

Who can join

18 and older, any sex, with Covid19 or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a registry-based cohort study of all adult patients (≥18 years) with confirmed or suspected SARS-CoV-2 infection. The main goal is to describe mortality incidence, demographic characteristics, coexisting conditions, treatments, outcomes among SARS-CoV2 infected patients. A secondary goal is to identify biological factors (OMICS - genomic, proteomic and metabolomics characterization) associated with severity conditions for these patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mortality, hospitalizations, and persistence of symptoms in the outpatient setting of the first COVID-19 wave in Brazil: results of SARS-Brazil cohort study.
Fonseca HAR, Pereira AJ, Pereira AJ, Nawa RK, et al · · 2024 · PMID 39140573 · DOI 10.31744/einstein_journal/2024ao0652

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hospital Israelita Albert Einstein trials

Trials by the same sponsor.

NCT07447674 — ED Post-Discharge Digital Follow-Up: A Communication Comparison · NA · not yet recruiting
NCT07398222 — Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study · recruiting
NCT07233837 — Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units · NA · recruiting
NCT06726707 — COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis · Phase 2, PHASE3 · withdrawn
NCT07112846 — Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04479488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Israelita Albert Einstein
Last refreshed: 9 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04479488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing